Late events after anti-CD19 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing published clinical trial and real-world data without systematic review methodology
PubMed 38919524 · doi:10.3389/fonc.2024.1404351
What was done
This narrative review synthesized published evidence from pivotal clinical trials and real-world cohort studies evaluating late adverse events (defined as persisting or occurring beyond 30 days post-infusion) in adults receiving anti-CD19 chimeric antigen receptor T-cell therapy (CART19) for relapsed or refractory B-cell non-Hodgkin lymphoma. The review focused on late cytopenias, immune reconstitution, hypogammaglobulinemia, infections, late neurotoxicity, and subsequent malignancies.
What was found
Grade 3–4 cytopenias were reported in 30%–40% of patients beyond 30 days and persisted beyond 90 days in 3%–22%. Hypogammaglobulinemia (IgG < 400 mg/dL) occurred in 44%–53% of patients, with approximately 27%–38% receiving intravenous immunoglobulin replacement. Infections after the first month were infrequent and rarely severe, though risk increased with subsequent anti-cancer therapies. Late neurotoxicity and neurocognitive impairment were uncommon. T-cell lymphoma was extremely rare, while post-treatment myeloid neoplasms occurred but lacked clear causal attribution due to extensive prior cytotoxic treatment.
Why it matters
It outlines the expected frequency of delayed toxicities after CART19, supporting routine monitoring for cytopenias and humoral immunodeficiency while noting that long-term non-relapse mortality remains low.
Limits
The abstract describes a narrative review rather than a formal systematic review or meta-analysis and omits total study and patient numbers. Distinguishing CAR T-cell-specific long-term adverse events from the toxicities of heavy prior chemotherapy remains challenging, especially for late cytopenias and secondary myeloid neoplasms.